View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 20, 2018updated 07 Aug 2019 2:34pm

Alector starts Phase l trial of AL001 for frontotemporal dementia

Alector has commenced a Phase l INFRONT trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 for the treatment of patients with Frontotemporal Dementia With Granulin Mutation (FTD-GRN).

Alector has commenced a Phase l INFRONT trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 for the treatment of patients with Frontotemporal Dementia With Granulin Mutation (FTD-GRN).

The randomised, parallel assignment trial intends to enrol 60 participants, including both healthy subjects and FTD-GRN patients.

During the trial, subjects will receive up to five single-ascending doses of AL001. Each cohort will also receive saline solution as a single infusion in a ratio of six active and two placebo subjects.

The trial’s primary goal is to determine safety and tolerability of AL001 measured by number of subjects with adverse events and dose-limiting adverse event (DLAEs).

Its secondary goals include pharmacokinetics, maximum plasma concentration, and area under the curve concentration (AUC).

“We look forward to progressing AL001 through clinical development towards our goal of bringing a new treatment option to patients in need.”

Alector chief medical officer Robert Paul said: “Our clinical trials are anchored in state-of-the-art biomarkers, brain imaging modalities, and cognitive tests that will allow us to monitor disease progression and treatment response rapidly and accurately.

“We look forward to progressing AL001 through clinical development towards our goal of bringing a new treatment option to patients in need.”

Frontotemporal dementia (FTD) is a common form of dementia that usually affects individuals who are less than 65 years old.

FTD is estimated to affect 65,000 individuals in the US and 110,000 individuals across the European Union.

The rapidly progressing degenerative syndrome results in prominent cognitive dysfunction, behavioural and personality changes, and language deficits.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena